Treatment of metastatic neuroendocrine carcinomas based on WHO classification

Salvatore Artale, Laura Giannetta, Giulio Cerea, Paolo Pedrazzoli, Ilaria Schiavetto, Marcello Napolitano, Silvio Veronese, Emanuela Bramerio, Marcello Gambacorta, Angelo Vanzulli, Salvatore Pisconti, Raffaele Pugliese, Salvatore Siena

Research output: Contribution to journalArticle

Abstract

A single institution prospective trial was conducted to evaluate the efficacy of biotherapy or chemotherapy in metastatic neuroendocrine carcinomas (NECs). The choice of therapy was based on the revised histological classification criteria of the WHO in an effort to define a standardized protocol for therapy of these cancers. Patients with well-differentiated NECs (WD-NECs; n=11) received therapy with octreotide long-acting release and interferon-α-2b for a maximum of 1 year; cases with poorly-differentiated NECs (PD-NECs; n=8) were given combination cisplatin, L-leucovorin and 5-fluorouracil chemotherapy for a maximum of 9 cycles. Five patients (4 with WD-NECs) had carcinoid syndrome. Among the patients with WD-NECs (median follow-up 20 months, range 4-40), 4 had partial responses and 7 had stable disease. In patients with PD-NECs (median follow-up 10.5 months, range 3-30), 3 had partial response, 2 stable disease, and the disease progressed in 3 cases. The 2-year survival rate in WD-NECs and PD-NECs was 88% and 66%, respectively. Grade 3-4 side-effects were limited to 9% thrombocytopenia and 12.5% neutropenia. Both these treatment regimens had a good therapeutic index and compared favourably with those previously reported for metastatic WD-NECs and PD-NECs.

Original languageEnglish
Pages (from-to)4463-4469
Number of pages7
JournalAnticancer Research
Volume25
Issue number6 C
Publication statusPublished - Nov 2005

Fingerprint

Neuroendocrine Carcinoma
Therapeutics
Drug Therapy
Biological Therapy
Octreotide
Leucovorin
Carcinoid Tumor
Neutropenia
Fluorouracil
Thrombocytopenia
Interferons
Cisplatin

Keywords

  • Biotherapy
  • Chemotherapy
  • Neuroendocrine carcinomas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Artale, S., Giannetta, L., Cerea, G., Pedrazzoli, P., Schiavetto, I., Napolitano, M., ... Siena, S. (2005). Treatment of metastatic neuroendocrine carcinomas based on WHO classification. Anticancer Research, 25(6 C), 4463-4469.

Treatment of metastatic neuroendocrine carcinomas based on WHO classification. / Artale, Salvatore; Giannetta, Laura; Cerea, Giulio; Pedrazzoli, Paolo; Schiavetto, Ilaria; Napolitano, Marcello; Veronese, Silvio; Bramerio, Emanuela; Gambacorta, Marcello; Vanzulli, Angelo; Pisconti, Salvatore; Pugliese, Raffaele; Siena, Salvatore.

In: Anticancer Research, Vol. 25, No. 6 C, 11.2005, p. 4463-4469.

Research output: Contribution to journalArticle

Artale, S, Giannetta, L, Cerea, G, Pedrazzoli, P, Schiavetto, I, Napolitano, M, Veronese, S, Bramerio, E, Gambacorta, M, Vanzulli, A, Pisconti, S, Pugliese, R & Siena, S 2005, 'Treatment of metastatic neuroendocrine carcinomas based on WHO classification', Anticancer Research, vol. 25, no. 6 C, pp. 4463-4469.
Artale S, Giannetta L, Cerea G, Pedrazzoli P, Schiavetto I, Napolitano M et al. Treatment of metastatic neuroendocrine carcinomas based on WHO classification. Anticancer Research. 2005 Nov;25(6 C):4463-4469.
Artale, Salvatore ; Giannetta, Laura ; Cerea, Giulio ; Pedrazzoli, Paolo ; Schiavetto, Ilaria ; Napolitano, Marcello ; Veronese, Silvio ; Bramerio, Emanuela ; Gambacorta, Marcello ; Vanzulli, Angelo ; Pisconti, Salvatore ; Pugliese, Raffaele ; Siena, Salvatore. / Treatment of metastatic neuroendocrine carcinomas based on WHO classification. In: Anticancer Research. 2005 ; Vol. 25, No. 6 C. pp. 4463-4469.
@article{071903b21177425a86e37855871f7149,
title = "Treatment of metastatic neuroendocrine carcinomas based on WHO classification",
abstract = "A single institution prospective trial was conducted to evaluate the efficacy of biotherapy or chemotherapy in metastatic neuroendocrine carcinomas (NECs). The choice of therapy was based on the revised histological classification criteria of the WHO in an effort to define a standardized protocol for therapy of these cancers. Patients with well-differentiated NECs (WD-NECs; n=11) received therapy with octreotide long-acting release and interferon-α-2b for a maximum of 1 year; cases with poorly-differentiated NECs (PD-NECs; n=8) were given combination cisplatin, L-leucovorin and 5-fluorouracil chemotherapy for a maximum of 9 cycles. Five patients (4 with WD-NECs) had carcinoid syndrome. Among the patients with WD-NECs (median follow-up 20 months, range 4-40), 4 had partial responses and 7 had stable disease. In patients with PD-NECs (median follow-up 10.5 months, range 3-30), 3 had partial response, 2 stable disease, and the disease progressed in 3 cases. The 2-year survival rate in WD-NECs and PD-NECs was 88{\%} and 66{\%}, respectively. Grade 3-4 side-effects were limited to 9{\%} thrombocytopenia and 12.5{\%} neutropenia. Both these treatment regimens had a good therapeutic index and compared favourably with those previously reported for metastatic WD-NECs and PD-NECs.",
keywords = "Biotherapy, Chemotherapy, Neuroendocrine carcinomas",
author = "Salvatore Artale and Laura Giannetta and Giulio Cerea and Paolo Pedrazzoli and Ilaria Schiavetto and Marcello Napolitano and Silvio Veronese and Emanuela Bramerio and Marcello Gambacorta and Angelo Vanzulli and Salvatore Pisconti and Raffaele Pugliese and Salvatore Siena",
year = "2005",
month = "11",
language = "English",
volume = "25",
pages = "4463--4469",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 C",

}

TY - JOUR

T1 - Treatment of metastatic neuroendocrine carcinomas based on WHO classification

AU - Artale, Salvatore

AU - Giannetta, Laura

AU - Cerea, Giulio

AU - Pedrazzoli, Paolo

AU - Schiavetto, Ilaria

AU - Napolitano, Marcello

AU - Veronese, Silvio

AU - Bramerio, Emanuela

AU - Gambacorta, Marcello

AU - Vanzulli, Angelo

AU - Pisconti, Salvatore

AU - Pugliese, Raffaele

AU - Siena, Salvatore

PY - 2005/11

Y1 - 2005/11

N2 - A single institution prospective trial was conducted to evaluate the efficacy of biotherapy or chemotherapy in metastatic neuroendocrine carcinomas (NECs). The choice of therapy was based on the revised histological classification criteria of the WHO in an effort to define a standardized protocol for therapy of these cancers. Patients with well-differentiated NECs (WD-NECs; n=11) received therapy with octreotide long-acting release and interferon-α-2b for a maximum of 1 year; cases with poorly-differentiated NECs (PD-NECs; n=8) were given combination cisplatin, L-leucovorin and 5-fluorouracil chemotherapy for a maximum of 9 cycles. Five patients (4 with WD-NECs) had carcinoid syndrome. Among the patients with WD-NECs (median follow-up 20 months, range 4-40), 4 had partial responses and 7 had stable disease. In patients with PD-NECs (median follow-up 10.5 months, range 3-30), 3 had partial response, 2 stable disease, and the disease progressed in 3 cases. The 2-year survival rate in WD-NECs and PD-NECs was 88% and 66%, respectively. Grade 3-4 side-effects were limited to 9% thrombocytopenia and 12.5% neutropenia. Both these treatment regimens had a good therapeutic index and compared favourably with those previously reported for metastatic WD-NECs and PD-NECs.

AB - A single institution prospective trial was conducted to evaluate the efficacy of biotherapy or chemotherapy in metastatic neuroendocrine carcinomas (NECs). The choice of therapy was based on the revised histological classification criteria of the WHO in an effort to define a standardized protocol for therapy of these cancers. Patients with well-differentiated NECs (WD-NECs; n=11) received therapy with octreotide long-acting release and interferon-α-2b for a maximum of 1 year; cases with poorly-differentiated NECs (PD-NECs; n=8) were given combination cisplatin, L-leucovorin and 5-fluorouracil chemotherapy for a maximum of 9 cycles. Five patients (4 with WD-NECs) had carcinoid syndrome. Among the patients with WD-NECs (median follow-up 20 months, range 4-40), 4 had partial responses and 7 had stable disease. In patients with PD-NECs (median follow-up 10.5 months, range 3-30), 3 had partial response, 2 stable disease, and the disease progressed in 3 cases. The 2-year survival rate in WD-NECs and PD-NECs was 88% and 66%, respectively. Grade 3-4 side-effects were limited to 9% thrombocytopenia and 12.5% neutropenia. Both these treatment regimens had a good therapeutic index and compared favourably with those previously reported for metastatic WD-NECs and PD-NECs.

KW - Biotherapy

KW - Chemotherapy

KW - Neuroendocrine carcinomas

UR - http://www.scopus.com/inward/record.url?scp=28444436906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444436906&partnerID=8YFLogxK

M3 - Article

C2 - 16334127

AN - SCOPUS:28444436906

VL - 25

SP - 4463

EP - 4469

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 C

ER -